| A269 |
Siltuximab Biosimilar (Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research. |
|
| A270 |
Olokizumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA). |
|
| A271 |
Clazakizumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. |
|
| A272 |
Chugai SK2 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A275 |
CSTRI patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A276 |
Medarex patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A277 |
MEDI 5117 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A278 |
Merck patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A129 |
Sarilumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis. |
|
| A280 |
APX-007 Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A281 |
Vobarilizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. |
|
| A282 |
Sapelizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A283 |
PF-06342674 Biosimilar(Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
|
|
| A284 |
Lusvertikimab Biosimilar（Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. |
|
| A285 |
Bapotulimab Biosimilar(Anti-ILDR2 Reference Antibody)
Featured
|
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects. |
|
| A286 |
Garetosmab Biosimilar(Anti-INHBA / Activin A Reference Antibody)
Featured
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. |
|
| A287 |
Oxford Brookes U. patent anti-Activin Beta-B Biosimilar(Anti-INHBB / Activin B Reference Antibody)
Featured
|
|
|
| A288 |
Scripps patent anti-CD11a Biosimilar(Anti-Integrin a11 / ITAG11 Reference Antibody)
Featured
|
|
|
| A289 |
Etrolizumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody)
Featured
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD). |
|
| A290 |
Briakinumab Biosimilar(Anti-IL-12 (IL-12a & IL-12b) Reference Antibody)
Featured
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. |
|
| A291 |
Nipocalimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6. |
|
| A292 |
Vatelizumab Biosimilar(Anti-Integrin a2b1 (ITGA2 & ITGB1) Reference Antibody )
Featured
|
Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). Vatelizumab can be used for the research of multiple sclerosis. |
|
| A294 |
Etaracizumab
Featured
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer. |
|
| A295 |
Orilanolimab
Featured
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity. |
|
| A296 |
Efalizumab
Featured
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research. |
|
| A297 |
Abituzumab
Featured
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer. |
|
| A298 |
Intetumumab
Featured
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer. |
|
| A299 |
Tadocizumab
Featured
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research. |
|
| A300 |
OS2966
Featured
|
|
|
| A301 |
Erlizumab
Featured
|
|
|
